• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

LentiGlobin Therapy for Sickle Cell Disease

January 4, 2022

Sickle cell disease (SCD) is caused by a single point mutation in the β-globin gene and affects around 100,000 people in the U.S.  SCD can be cured in 14-20% of younger patients who have an HLA-matched donor, but allogeneic hematopoietic stem-cell transplants also carry risk of graft-versus-host disease, graft rejection, and even death.  Based on ongoing phase 1-2 clinical trials, LentiGlobin (a lentiviral vector encoding a modified β-globin gene HbAT87Q) therapy holds promise to treat even more patients with SCD and reduce painful vaso-occlusive events.  As reported in The New England Journal of Medicine, hematopoetic stem cells were collected and infected with LentiGlobin from 35 patients with SCD (all with βs/ βs genotype) with a minimum of four severe vaso-occlusive events in the past two years before study enrollment (median age, 24 years; 37% female).  Patients with autologous LentiGlobin infusions were followed for 6 months to 3 years (median follow-up, 17.3 months); engraftment occurred in all patients.  Vector copy number was stable in all patients up to 3 years; total hemoglobin levels increased from 8.5 g/dL to at least 11 g/dL over the course of the study; a mean of 85% of the red cells expressed HbAT87Q and contributed to at least 40% of the total hemoglobin; hemolysis markers also decreased.  Importantly, all patients had resolution of severe vaso-occlusive events, severe adverse events all resolved within one week of onset, and no cases of hematologic cancer were observed.  Follow-up is needed to determine the long-term effectiveness and risks of LentiGlobin therapy.

Reference:

Kanter J, Walters MC, Krishnamurti L, Mapara MY, et al.  Biological and clinical efficacy of LentiGlobin for sickle cell disease.  NEJM 2021

Filed Under

  • Cell Therapy
  • News

Recommended

  • CRISPR-Cas9 Gene Editing and Lentiviral Gene Therapy Hold Promise to Treat Transfusion Dependent β-Globin Hemoglobinopathies

  • Most Blood Donors Are Motivated by Altruism

  • High Variability in Antibody Titer Determination in Transfusion Medicine

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley